May 11, 2022 – But recent studies showing great promise in psychedelics are prompting startups to develop new health drugs in the space. Venture capitalists are also taking note. 

Dr. Carolyn Rodriguez from the Stanford University School of Medicine explained that traditional treatment methods from Selective Serotonin Reuptake Inhibitors (SSRIs) like Prozac and cognitive behavioral therapy don’t always work for some patients. Psychedelics are showing immense potential as an antidote for those who are suffering. Rodriguez shared the story of a young patient called John who suffered from OCD and intrusive thoughts that damaged his academic life and personal relationships. 

“He was not able to function,” she said. 

Countless people like John are resistant to first-line treatments and psychedelics like Ketamine may be an option for relief, she said. Dr. Rodriguez performed the first randomized, controlled proof-of-concept study of Ketamine in low doses through IV infusion in OCD patients. 


[ninja-popup ID=12216]